X. Steven Wan
Department of Radiation Oncology
University of Pennsylvania School of Medicine
Philadelphia 19104
USA
Name/email consistency: high
- Three immunoassays based on monoclonal antibodies specific for prostate specific antigen (PSA), alpha-1-antichymotrypsin (ACT), and the PSA-ACT complex. Wan, X.S., Xu, Y.A., Ware, J.H., Kennedy, A.R. Prostate (2003)
- In vitro evaluation of chemopreventive agents using cultured human prostate epithelial cells. Wan, X.S., Zhou, Z., Kennedy, A.R., Kopelovich, L. Oncol. Rep. (2003)
- Detection of Bowman-Birk inhibitor and anti-Bowman-Birk inhibitor antibodies in sera of humans and animals treated with Bowman-Birk inhibitor concentrate. Wan, X.S., Serota, D.G., Ware, J.H., Crowell, J.A., Kennedy, A.R. Nutr. Cancer (2002)
- Urinary excretion of Bowman-Birk inhibitor in humans after soy consumption as determined by a monoclonal antibody-based immunoassay. Wan, X.S., Lu, L.J., Anderson, K.E., Ware, J.H., Kennedy, A.R. Cancer Epidemiol. Biomarkers Prev. (2000)
- Relationship between protease activity and neu oncogene expression in patients with oral leukoplakia treated with the Bowman Birk Inhibitor. Wan, X.S., Meyskens, F.L., Armstrong, W.B., Taylor, T.H., Kennedy, A.R. Cancer Epidemiol. Biomarkers Prev. (1999)
- Treatment with soybean-derived Bowman Birk inhibitor increases serum prostate-specific antigen concentration while suppressing growth of human prostate cancer xenografts in nude mice. Wan, X.S., Ware, J.H., Zhang, L., Newberne, P.M., Evans, S.M., Clark, L.C., Kennedy, A.R. Prostate (1999)